To compare anticoagulant (AC) treatment with anti-platelet treatment in the prevention of cerebral infarction in patients with transient ischemic attacks or reversible ischemic deficit.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
- Warfarin (Coumadin®)Drug
Other Names: Coumadin Intervention Desc: Anticoagulant (Vitamin K antagonist)
Prospective, randomized trial of 156 patients at 5 centers.
All patients were given AC treatment with coumadin for 2 months in addition to heparin infusion (20-40000 IU/day based on maintaining arterial thromboplastin time <= 100s) during the first 4-5 days of treatment. After 2 months, the remaining patients were randomized to continue with AC treatment or to switch to anti-platelet therapy for 12 months. The AC treatment was controlled with the TT-test to a therapeutic range between 7-15% of normal. The anti-platelet therapy consisted of acetylsalicylic acid (0.5 g x 2) plus dipyridamole (75 mg x 2). Patients with new cerebral symptoms and blood-salicylate < 0.1 mmol/l were given higher doses of acetylsalicylic acid and dipyridamole.
|Type||Measure||Time Frame||Safety Issue|
|No outcomes associated with this trial.|